Related Experiment Video
Updated: Jun 19, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
A study of reported factor VIII use around the world
J S Stonebraker1, M Brooker, R E Amand
1College of Management, North Carolina State University, Raleigh, NC 27695-7229, USA. jeff_stonebraker@ncsu.edu
Summary
Factor VIII (FVIII) concentrate use varies globally, increasing with economic capacity. This trend highlights the need for healthcare planning and pharmaceutical production adjustments to meet rising global demand for haemophilia A treatment.
Area of Science:
- Hematology
- Global Health
- Pharmacoeconomics
Background:
- Haemophilia A treatment significantly reduces morbidity and mortality in high-income nations.
- Developing countries face challenges in haemophilia A treatment due to low visibility and high costs, leading to severe health consequences.
- Factor VIII (FVIII) replacement therapy is crucial for managing haemophilia A.
Purpose of the Study:
- To analyze country-by-country reported Factor VIII (FVIII) concentrate usage.
- To identify trends in FVIII consumption globally.
- To inform healthcare resource allocation and pharmaceutical production planning.
Main Methods:
- Collected FVIII use data for 104 countries.
- Utilized data from Marketing Research Bureau, Inc. and the World Federation of Hemophilia.
- Analyzed FVIII usage in relation to country economic capacity.
Main Results:
- Significant variation in FVIII use exists across countries, including high-income nations.
- FVIII concentrate consumption correlates positively with a country's economic capacity.
- Consumption of FVIII is increasing at a faster rate in high-income countries.
- A global increase in FVIII concentrate usage is projected.
Conclusions:
- Global FVIII concentrate usage is expected to rise, driven by economic development.
- Data on FVIII use is critical for national healthcare agencies to prioritize budgets and resources for haemophilia A treatment.
- Pharmaceutical manufacturers require this information for production planning to meet anticipated demand.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:08Prevalence and Incidence
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...